Overview

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Status:
Recruiting
Trial end date:
2034-09-01
Target enrollment:
Participant gender:
Summary
Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy. Adjuvant chemotherapy with ifosfamide and doxorubicin may improve long-term disease-free survival, but the benefit of adjuvant treatment is limited and predictive factors for treatment response are lacking. The aim of this study is to explore sequential treatment with ifosfamide and doxorubicin in a neoadjuvant setting and to investigate biomarkers predictive of treatment response.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborator:
Haukeland University Hospital
Treatments:
Doxorubicin
Ifosfamide